Home >
Publications/Products > HIV/Hepatitis C Coinfection Guidelines
for Health Care Providers
Table 5. Assays for Quantitation of HCV RNA in Serum and Their Dynamic Range
Back to Management and Treatment of Hepatitis C Virus Infection in HIV-Infected Adults
| Assay | Conversion 1 IU/mL = X copies/mL | Technique | Dynamic Range (IU/mL) |
|---|---|---|---|
| Adapted from the AASLD Guidelines (17) Roche Molecular Systems, Branchburg, NJ; Bayer Diagnostics, Tarrytown, NY; Abbot Diagnostics, Chicago, IL; National Genetics Institute, Los Angeles, CA. | |||
| AMPLICOR HCV Monitor V2.0 (Roche molecular systems) | 0.9 | Manual competitive reverse transcriptase PCR (rtPCR) | 600-500,000 |
| COBAS AMPLICOR HCV Monitor V2.0 (Roche molecular systems) | 2.7 | Semi-automated competitive rtPCR | 600-500,000 |
| Versant HCV RNA 3.0 quantitative assay (Bayer diagnostics) | 5.2 | Semi-automated 'branched DNA' assay | 615-7,690,000 |
| LCx HCV RNA quantitative assay (Abbot diagnostics) | 3.8 | Semi-automated competitive rtPCR | 25-2,630,000 |
| SuperQuant (National Genetics Institute) | 3.4 | Semi-automated competitive rtPCR | 30-1,470,000 |
From Management and Treatment of Hepatitis C Virus Infection in HIV-Infected Adults
Hepatitis C Resource Center Program and National Hepatitis C Program Office
September 2005
